I-Mab Biopharma
I-Mab is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases.
Launch date
Employees
Market cap
CAD112m
Enterprise valuation
(CAD165m) (Public information from Sep 2024)
Share price
$1.11 IMAB
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.5b | 88.0m | (222m) | 3.9m | 18.9m | 26.2m | - |
| % growth | 5042 % | (94 %) | (352 %) | (102 %) | 385 % | 38 % | - |
| EBITDA | 484m | (2.3b) | (2.4b) | (169m) | (800m) | - | - |
| % EBITDA margin | 31 % | (2652 %) | 1088 % | (4340 %) | (4231 %) | - | - |
| Profit | 471m | (2.3b) | (2.4b) | (207m) | (256m) | (608m) | (771m) |
| % profit margin | 31 % | (2649 %) | 1089 % | (5302 %) | (1352 %) | (2323 %) | - |
| EV / revenue | 15.7x | 255.5x | 4.9x | 294.1x | 35.1x | 25.3x | - |
| EV / EBITDA | 49.9x | -9.6x | 0.5x | -6.8x | -0.8x | - | - |
| R&D budget | 985m | 1.2b | 905m | 114m | - | - | - |
| R&D % of revenue | 64 % | 1378 % | (408 %) | 2932 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Series A | ||
$150m | Series B | ||
$220m Valuation: $880m 513.7x EV/LTM Revenues -20.4x EV/LTM EBITDA | Series C | ||
$27.0m | Series C | ||
| N/A | $104m Valuation: $807m 195.6x EV/LTM Revenues -4.1x EV/LTM EBITDA | IPO | |
$418m | Private Placement VC | ||
* | CNY500m | Post IPO Equity | |
| Total Funding | CAD1.1b | ||
Related Content
Recent News about I-Mab Biopharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
